



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/04, A61K 39/00, 48/00	A1	(11) International Publication Number: WO 98/18812 (43) International Publication Date: 7 May 1998 (07.05.98)
(21) International Application Number: PCT/US97/15397 (22) International Filing Date: 29 August 1997 (29.08.97) (30) Priority Data: 08/740,215 25 October 1996 (25.10.96) US (71) Applicant: HISAMITSU PHARMACEUTICAL CO., INC. [US/US]; 2732 Loker Avenue W., W. Carlsbad, CA 92008 (US). (72) Inventors: VEERAPANANE, Dange; 3922 Caminito Delmar Cove, San Diego, CA 92130 (US). HAMANAKA, Shoji; 1-7, Maborikaigan, Yokosuka, Kanagawa 238 (JP). NOZAWA, Iwao; 4-15-3, Kamiyuma, Setagaya, Tokyo 340 (JP). (74) Agent: COLLINS, John, M.; Hovey, Williams, Timmons & Collins, Suite 400, 2405 Grand Boulevard, Kansas City, MO 64108 (US).		(81) Designated States: AU, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: OLIGOMERS WHICH INHIBIT THE EXPRESSION OF INTERLEUKIN GENES (57) Abstract Oligomers for inhibiting expression of interleukin genes are described. It is believed that each oligomer, when introduced into a cell, is capable of forming a transcription-inhibiting complex composed of the oligomer and an interleukin gene. The oligomer preferably binds in the antiparallel orientation to the polypurine strand of a polypurine-polypyrimidine region of the interleukin gene.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SEQUENCE LISTING

BACKGROUND OF THE INVENTION

immunoglobulin M (anti-IgM) (Armitage et al., 1995, J. Immunol. 154:483-490), stimulates locomotion and chemotaxis of normal T cells (Wilkinson et al., 1995, J. Exp. Med. 181:1255-1259), and promotes interleukin-5 production by T cells which may contribute to eosinophilic inflammation (Mori et al., 1996, J. Immunol. 156:2400-2405). Persistent eosinophilic inflammation in the bronchial mucosa is well recognized in the pathogenesis of chronic asthma (Bousquet et al., 1990, N. Engl. J. Med. 323:1033).

Rheumatoid arthritis is a destructive inflammatory polyarthropathy (Maini et al., 1995, in Mechanisms and Models in Rheumatoid Arthritis, pp. 25-26, eds. Henderson, Edwards, and Pettifer, Academic Press, London, 25-26). Chronic rheumatoid synovitis is characterized by the presence of activated fibroblast-like synoviocytes together with infiltration of the normally acellular synovial membrane by macrophages, T cells, and plasma cells (Duke et al., 1982, Clin. Exp. Immunol. 49:22-30). Levels of interleukin-15 in rheumatoid arthritis synovial fluid are sufficient to exert chemoattractant activity on T cells *in vitro*, and can induce proliferation of peripheral blood and synovial T cells; furthermore, interleukin-15 induces an inflammatory infiltrate consisting predominantly of T lymphocytes (McInnes et al., 1996, Nature Medicine 2:175-182). Therapies directed at T cells, such as cyclosporin A and monoclonal antibodies against T-cell surface antigens, produce significant clinical improvement, confirming the importance of T cells in inflammatory polyarthropathy (Horneff et al., 1991, Arth. Rheum. 34:129-140; Wendling et al., 1991, J. Rheumatol. 18:325-327; Harrison et al., 1992, in Second-line Agents in the Treatment of Rheumatic Diseases, eds. Dixon and Furst, Dekker, New York). Thus, it appears that interleukin-15 plays a significant role in T-cell recruitment and activation in inflammatory polyarthropathy.

Oligomers (i.e., oligonucleotides and oligonucleotide analogs such as protein nucleic acid) are reagents for inhibition of gene expression because of their high-affinity binding to specific nucleotide sequences. The best known strategy for causing inhibition of gene expression involves antisense oligonucleotides which bind to mRNA to inhibit its processing or translation. For example, it has been shown that the expression of the human $\alpha 1(I)$ collagen gene is effectively inhibited by antisense oligonucleotides targeted at specific regions of the $\alpha 1(I)$ mRNA (Laptev et al., 1994, Biochemistry 33:11033-11039).

Additionally, gene promoters can serve as targets for a novel, antisense strategy, namely the triplex strategy. This strategy employs single-stranded oligomers that bind to the major groove of a polypurine-polypyrimidine region of a double-stranded DNA to form a triplex in a sequence-specific manner. These oligomers are called triplex-

forming oligonucleotides (TFO's) or TFO analogs. In a polypurine-polypyrimidine region, a purine-rich DNA single strand is hydrogen bonded by Watson-Crick base-pairing to a pyrimidine-rich DNA single strand; the polypurine-polypyrimidine region is not necessarily a homopurine-homopyrimidine region in that the purine-rich DNA single strand may contain at least one pyrimidine residue and the pyrimidine-rich DNA single strand may contain at least one purine residue. These triplexes have been shown to inhibit transcriptional activity of various promoters in both *in vitro* and *in vivo* experiments (Grigoriev et al., 1992, J. Biol. Chem. 267:3389-95; Cooney et al., 1988, Science 241:456-59; Maher et al., 1989, Science 245:725-30; Ing et al., 1993, Nucleic Acids Res. 21:2789-96; Kovacs et al., 1996, J. Biol. Chem. 271:1805-1812). However, the use of oligomers to inhibit transcription of interleukin genes and to thereby suppress T-cell recruitment and activation as a method of treating inflammatory polyarthropathy is unknown in the prior art.

SUMMARY OF THE INVENTION

The present invention provides novel therapies for inflammatory polyarthropathy associated with rheumatoid arthritis and eosinophilic inflammation associated with chronic asthma. In these therapies, expression of interleukin genes is inhibited, resulting in suppression of T-cell recruitment and activation, and a concomitant alleviation of inflammatory polyarthropathy or eosinophilic inflammation.

In the present invention, a sequence-specific oligomer is introduced into a cell resulting in the production of a transcription-inhibiting complex composed of the oligomer bound to the interleukin gene. These oligomers include oligonucleotides (e.g., phosphodiester, phosphorothioate, methylphosphonate, and methylphosphonothioate oligonucleotides) and oligonucleotide analogs [e.g., protein nucleic acid, morpholino, methylene (methylimino) linkage, boronated, and pteridine oligomers]. Oligonucleotide analogs can be linked at either their 5' or 3' ends to intercalators (e.g., psoralen and acridine derivatives). Oligomers can be formulated into pharmaceutically acceptable preparations (e.g., injectable preparations, sprays, ointments, creams, gels, tablets, and perfusions).

In preferred embodiments, the oligomer is a phosphorothioate oligodeoxynucleotide having a length of at least about 5 nucleotides, preferably from about 5 to 50 nucleotides; this oligonucleotide preferably binds in the antiparallel orientation to the polypurine strand of a polypurine-polypyrimidine region of the transcribed region of the interleukin-15 gene.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a photograph of an autoradiogram of a gel illustrating the results of a gel mobility shift analysis of oligonucleotide-directed triplex formation on a target DNA specific to the transcribed region of the interleukin-15 gene; sequence ID No. 1 was end-labeled and incubated with an excess of unlabeled Sequence ID No. 3; each reaction mixture was either incubated overnight at 22°C and included 0.1 µg (lane 1), 0.2 µg (lane 2), 0.4 µg (lane 3), 0.8 µg (lane 4), or 1.6 µg (lanes 5 and 6) of Sequence ID No. 3, or each reaction mixture was incubated overnight at 37°C and included 0.1 µg (lane 7), 0.2 µg (lane 8), 0.4 µg (lane 9), 0.8 µg (lane 10), or 1.6 µg (lane 11) of Sequence ID No. 3; D = duplex DNA and T = triplex DNA; and

Fig. 2 is a photograph of an autoradiogram of a gel illustrating the results of a gel mobility shift analysis of oligonucleotide-directed triplex formation on a target specific to the transcribed region of the interleukin-15 gene; Sequence ID No. 1 was end-labeled and incubated with an excess of unlabeled Sequence ID No. 3; each reaction mixture was incubated for 3 h at 22°C and included 0 µg (lanes 1 and 7), 0.05 µg (lane 2), 0.1 µg (lane 3), 0.2 µg (lane 4), 0.4 µg (lane 5), or 0.8 µg (lane 6) of Sequence ID No. 3; D = duplex DNA and T = triplex DNA.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The following example describes preferred techniques for the synthesis of the therapeutic oligomers of the present invention, and use thereof in the inhibition of interleukin-gene expression; it is to be understood, however, that these examples are provided by way of illustration only, and nothing therein should be taken as a limitation upon the overall scope of the invention.

EXAMPLE

Materials and Methods

Oligonucleotide Synthesis and Preparation:

Oligonucleotides were synthesized on an Applied Biosystems 392 DNA synthesizer. Double-stranded oligonucleotides were prepared by mixing equal amounts of complementary single strands in the presence of 0.25 M NaCl. The mixture was heated to 80°C for 5 min, incubated at 55°C for 30 min, and then at 42°C for 30 min. Oligonucleotides were gel purified on a 10% polyacrylamide gel, electroeluted, and precipitated with ethanol.

Table 1 describes the double-stranded oligonucleotides (i.e., target DNAs) of the present invention:

Sequence ID No. of Oligonucleotide	Parent Gene	Nucleotide Position in Parent Gene
1	interleukin-15 gene	184 to 205
2	interleukin-15 gene	1924 to 1940

Table 2 describes the single-stranded oligonucleotides (i.e., TFO's) of the present invention:

Sequence ID No. of Oligonucleotide	Type	Orientation Relative to Target DNA	Sequence ID No. of Target DNA
3	phosphodiester	antiparallel	1
4	phosphodiester	parallel	1
5	phosphodiester	antiparallel	2
6	phosphodiester	parallel	2

Gel Mobility Shift Analysis of Triplex Formation:

Sequence ID No. 1 was end-labeled with [$\alpha^{32}\text{P}$]ATP using T_4 polynucleotide kinase, and was purified through a Sephadex G50 column. Approximately 30,000 cpm was incubated with 0 to 1.6 μg of Sequence ID No. 3 in a 10 μl reaction mixture including 20 mM Tris-HCl (pH 7.4), 20 mM MgCl_2 , 2.5 mM spermidine, 10% sucrose, and 0.25 mg/ml bovine serum albumin. Incubation was conducted overnight at 22°C or 37°C, or was conducted for 3 h at 22°C. Samples were electrophoresed through 8% polyacrylamide, 0.25% bisacrylamide gels buffered with 89 mM Tris, 89 mM boric acid (pH 7.5), and 20 mM MgCl_2 for 4.5 h at 10 V/cm at 6°C. Gels were then dried and autoradiographed.

Gel Mobility Shift Analyses are conducted as described above using Sequence ID No. 1 as double-stranded target DNA and Sequence ID No. 4 as single-stranded oligonucleotide, and using Sequence ID No. 2 as double-stranded target DNA and Sequence ID Nos. 5 and 6 as single-stranded oligonucleotides.

Results and Discussion

Sequence ID No. 3 Forms a Triplex with Sequence ID No. 1:

5 The 21-bp long polypyrimidine sequence of the transcribed region of the human interleukin-15 gene occurring at nucleotide positions 184 to 205 is a rare structure; such long stretches of all C's and T's occur infrequently in other genes. It was hypothesized that a single-stranded oligonucleotide with a sequence complementary to the polypyrimidine sequence of the interleukin-15 gene would be able to form a triplex with this structure. In order to demonstrate triplex formation with this target sequence, gel mobility shift assays were performed. The detection of a triplex structure in this electrophoresis system is based on the observation that triplex DNA migrates more slowly in a polyacrylamide gel relative to duplex DNA due to the reduction of DNA charge that is likely to accompany triplex formation.

10 Initial testing of triplex formation was performed using a single-stranded oligonucleotide (i.e., Sequence ID No. 3) having a sequence identical to the polypurine strand of the double-stranded target sequence (i.e., Sequence ID No. 1). Radiolabeled Sequence ID No. 1 was incubated with increasing amounts of Sequence ID No. 3. The results of this gel mobility shift analysis are shown in Figs. 1 and 2. These figures demonstrate that the addition of increasing amounts of Sequence ID No. 3 relative to Sequence ID No. 1 results in a gradual shift from duplex (D) to a distinct slower-migrating band (T), indicating the formation of triplex DNA. Such triplex formation within the transcribed region of the interleukin-15 gene shows that oligonucleotide-directed triplex formation has utility in inhibiting elongation of primary transcripts in addition to inhibiting initiation of the synthesis of these transcripts.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Veerapanane, Dange
Hamanaka, Shoji
Nozawa, Iwao
- (ii) TITLE OF INVENTION: OLIGOMERS WHICH INHIBIT
EXPRESSION OF INTERLEUKIN GENES
- (iii) NUMBER OF SEQUENCES: 6
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Hovey, Williams, Timmons & Collins
 - (B) STREET: 2405 Grand Boulevard, Suite 400
 - (C) CITY: Kansas City
 - (D) STATE: Missouri
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 64108
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Collins, John M.
 - (B) REGISTRATION NUMBER: 26262
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (816) 474-9050
 - (B) TELEFAX: (816) 474-9057

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TTCCCTTTCT TTCTTTTCT T

21

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CTTTTTTCTT CTCTCTT

17

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AAGGGAAAGA AAGAAAAAGA A

21

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AAGAAAAAGA AAGAAAGGGA A

21

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GAAAAAAGAA GAGAGAA

17

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AAGAGAGAAG AAAAAAG

17

Claims:

1. An oligomer capable of inhibiting expression of an interleukin gene.
2. The oligonucleotide of claim 1, wherein the gene is an interleukin-15
5 gene.
3. The oligomer of claim 1, wherein the oligomer is capable of alleviating
inflammatory polyarthopathy.
4. The oligomer of claim 3, wherein the inflammatory polyarthopathy is
10 associated with rheumatoid arthritis.
5. The oligomer of claim 1, wherein the oligomer is capable of alleviating
eosinophilic inflammation.
15
6. The oligomer of claim 5, wherein the eosinophilic inflammation is
associated with chronic asthma.
7. The oligomer of claim 1, wherein the oligomer is selected from the group
20 consisting of an oligonucleotide and an oligonucleotide analog.
8. The oligomer of claim 7, wherein the oligonucleotide analog is selected
from the group consisting of protein nucleic acid, morpholino, methylene linkage,
boronated, and pteridine oligonucleotide analogs.
25
9. The oligomer of claim 7, wherein the oligonucleotide analog is linked
at its 5' end or 3' end to an intercalator.
10. The oligomer of claim 9, wherein the intercalator is selected from the
30 group consisting of psoralen and acridine derivatives.
11. The oligomer of claim 7, wherein the oligomer is an oligonucleotide.
12. The oligonucleotide of claim 11, wherein the oligonucleotide is DNA.
35

13. The oligonucleotide of claim 11, wherein the oligonucleotide is selected from the group consisting of phosphodiester, phosphorothioate, methylphosphonate, and methylphosphonothioate oligonucleotides.

5 14. The oligonucleotide of claim 13, wherein the oligonucleotide is a phosphodiester oligonucleotide.

15. The oligonucleotide of claim 11, wherein the oligonucleotide is at least about 5 nucleotides in length.

10 16. The oligonucleotide of claim 15, wherein the length is from about 5 to 50 nucleotides.

15 17. The oligonucleotide of claim 11, wherein the oligonucleotide is capable of binding to the transcribed region of the gene.

18. The oligonucleotide of claim 17, wherein the oligonucleotide is capable of binding to a polypurine-polypyrimidine region of the transcribed region.

20 19. The oligonucleotide of claim 18, wherein the polypurine-polypyrimidine region comprises a sequence selected from the group consisting of Sequence ID Nos. 1 and 2.

25 20. The oligonucleotide of claim 19, wherein the oligonucleotide comprises a sequence selected from the group consisting of Sequence ID Nos. 3 through 6 .

21. The oligonucleotide of claim 18, wherein the oligonucleotide is capable of binding to the polypurine strand of the polypurine-polypyrimidine region.

30 22. The oligonucleotide of claim 21, wherein the oligonucleotide is capable of binding to the polypurine strand in a parallel orientation.

23. The oligonucleotide of claim 21, wherein the oligonucleotide is capable of binding to the polypurine strand in an antiparallel orientation.

35 24. A complex comprising an oligomer bound to an interleukin gene.

25. The complex of claim 24, wherein the gene is an interleukin-15 gene.

26. The complex of claim 24, wherein the oligomer is selected from the group consisting of an oligonucleotide and an oligonucleotide analog.

5

27. The complex of claim 26, wherein the oligonucleotide analog is selected from the group consisting of protein nucleic acid, morpholino, methylene linkage, boronated, and pteridine oligonucleotide analogs.

10

28. The complex of claim 26, wherein the oligonucleotide analog is linked at its 5' end or 3' end to an intercalator.

29. The complex of claim 28, wherein the intercalator is selected from the group consisting of psoralen and acridine derivatives.

15

30. The complex of claim 26, wherein the oligomer is an oligonucleotide.

31. The complex of claim 30, wherein the oligonucleotide is DNA.

20

32. The complex of claim 30, wherein the oligonucleotide is selected from the group consisting of phosphodiester, phosphorothioate, methylphosphonate, and methylphosphonothioate oligonucleotides.

25

33. The complex of claim 32, wherein the oligonucleotide is a phosphodiester oligonucleotide.

34. The complex of claim 32, wherein the oligonucleotide is at least about 5 nucleotides in length.

30

35. The complex of claim 34, wherein the length is from about 5 to 50 nucleotides.

36. The complex of claim 32, wherein the oligonucleotide is capable of binding to the transcribed region of the gene.

35

37. The complex of claim 36, wherein the oligonucleotide is capable of binding to a polypurine-polypyrimidine region of the transcribed region.

38. The complex of claim 37, wherein the polypurine-polypyrimidine region comprises a sequence selected from the group consisting of Sequence ID Nos. 1 and 2.

39. The complex of claim 38, wherein the oligonucleotide comprises a sequence selected from the group consisting of Sequence ID Nos. 3 through 6 .

40. The complex of claim 37, wherein the oligonucleotide is capable of binding to the polypurine strand of the polypurine-polypyrimidine region.

41. The complex of claim 40, wherein the oligonucleotide is capable of binding to the polypurine strand in a parallel orientation.

42. The complex of claim 40, wherein the oligonucleotide is capable of binding to the polypurine strand in an antiparallel orientation.

43. A method of inhibiting expression of an interleukin gene comprising the steps of:
inserting an oligomer into a cell; and
causing an intracellular reaction which inhibits the expression of the interleukin gene.

44. The method of claim 43, wherein the gene is an interleukin-15 gene.

45. The method of claim 43, wherein the oligomer is dispersed in a pharmaceutically acceptable carrier.

46. The method of claim 45, wherein the carrier is selected from the group consisting of injectable preparations, sprays, ointments, creams, gels, tablets, and perfusions.

47. The method of claim 43, wherein the oligomer is selected from the group consisting of an oligonucleotide and an oligonucleotide analog.

48. The method of claim 47, wherein the oligonucleotide analog is selected from the group consisting of protein nucleic acid, morpholino, methylene linkage, boronated, and pteridine oligonucleotide analogs.

5 49. The method of claim 47, wherein the oligonucleotide analog is linked at its 5' end or 3' end to an intercalator.

50. The method of claim 49, wherein the intercalator is selected from the group consisting of psoralen and acridine derivatives.

10 51. The method of claim 47, wherein the oligomer is an oligonucleotide.

52. The method of claim 51, wherein the oligonucleotide is DNA.

15 53. The method of claim 51, wherein the oligonucleotide is selected from the group consisting of phosphodiester, phosphorothioate, methylphosphonate, and methylphosphonothioate oligonucleotides.

20 54. The method of claim 53, wherein the oligonucleotide is a phosphodiester oligonucleotide.

55. The method of claim 51, wherein the oligonucleotide is at least about 5 nucleotides in length.

25 56. The method of claim 55, wherein the length is from about 5 to 50 nucleotides.

57. The method of claim 51, wherein the oligonucleotide is capable of binding to the transcribed region of the gene.

30 58. The method of claim 57, wherein the oligonucleotide is capable of binding to a polypurine-polypyrimidine region of the transcribed region.

35 59. The method of claim 58, wherein the polypurine-polypyrimidine region comprises a sequence selected from the group consisting of Sequence ID Nos. 1 and 2.

60. The method of claim 59, wherein the oligonucleotide comprises a sequence selected from the group consisting of Sequence ID Nos. 3 through 6 .

5 61. The method of claim 58, wherein the oligonucleotide is capable of binding to the polypurine strand of the polypurine-polypyrimidine region.

62. The method of claim 61, wherein the oligonucleotide is capable of binding to the polypurine strand in a parallel orientation.

10 63. The method of claim 61, wherein the oligonucleotide is capable of binding to the polypurine strand in an antiparallel orientation.

1/1




FIG. 1.




FIG. 2.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/15397

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/04; A61K 39/00; A61K 48/00

US CL : 536/24.5, 23.1, 23.3, 23.31, 23.33; 514/44; 424/184.1; 435/375

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/24.5, 23.1, 23.3, 23.31, 23.33; 514/44; 424/184.1+; 435/375

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN/CAS: MEDLINE, BIOSIS

search terms: oligo?, IL?, INTERLEUKIN?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	SALERNO et al. Interleukin-4 is a critical cytokine in contact sensitivity. Immunology, 1995, Vol. 84, 404-409, especially Summary, lines 6-7.	1, 7, 11-16, 43, 45-47, 51-56 ----- 8, 27, 48
X ----- Y	LOUIE et al. Endogenous secretion of IL-4 maintains growth and Thy-1 expression of a transformed B cell clone. J. Immunol. June, 1993, Vol. 150, page 399-406, see Abstracts, lines 10-14.	1, 7, 11-16, 43, 45-47, 51-56 ----- 8, 27, 48; 9, 10, 28, 29, 49, 50.



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

17 DECEMBER 1997

Date of mailing of the international search report

23 FEB 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Hsiu-Ming Saunders

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/15397

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ASSELINE et al. Nucleic acid-binding molecules with high affinity and base sequence specificity: Intercalating agents covalently linked to oligodeoxynucleotides. Proc. Natl. Acad. Sci., June 1984, Vol. 81, pages 3297-3301, especially Abstracts.	9, 10, 28, 29, 49, 50
Y	HANVEY et al. Antisense and Antigene Properties of Peptide Nucleic Acids. Science, 1992, Vol. 258, pages 1481-1485, especially page 1483, second paragraph, lines 7-14.	8, 27, 48
Y	Young et al. Triple helix formation inhibits transcription elongation in vitro. Proc. Natl. Acad. Sci. November, 1991, Vol. 88, pages 10023-10026, especially Abstracts and Introduction, lines 1-3.	1, 2, 7, 11-18, 21, 23-26, 30-37, 40, 42-47, 51-58, 61, 63
Y	Grabstein et al. Cloning of a T Cell Growth Factor that Interacts with the beta Chain of the Interleukin-2 Receptor. Science, May, 1994, Vol. 264, pages 965-968. Abstracts.	1, 2, 7, 11-18, 21, 23-26, 30-37, 40, 42-47, 51-58, 61, 63

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

